1. Home
  2. SPRINT PNS System
Shoulder image Shoulder image

Short-term treatment. Designed for long-term relief.™ 

The SPR® SPRINT® PNS System is a 60-day PNS solution for durable pain relief with more data and more applications than any other PNS system available.

SPRINT PNS product SPRINT PNS product

Low-risk. Non-surgical. Durable.*

Uniquely designed to selectively stimulate targeted peripheral nerve fibers for up to 60 days, the SPRINT PNS System delivers a low-risk, non-surgical, minimally invasive and drug-free pain treatment option proven in clinical studies to provide significant and sustained relief from moderate to severe acute and chronic pain. 

*Refer to the Indications for Use  page for the SPRINT System’s two indications for use statements and clinical data supporting durable pain relief.

  • Short-term, 60-day treatment

  • Potential for durable relief

  • No permanent implant 

  • Minimally invasive and drug-free

  • Non-destructive, motor-sparing

Download the Brochure
70 percent graphic

Clinically proven pain relief

In clinical studies, the vast majority of SPRINT PNS patients reported significant and sustained relief of pain and/or pain interference.1-11, The most common adverse events were skin irritation and erythema.

71 percent graphic 71 percent graphic

Backed by the largest review of real-world PNS data

The largest retrospective review of real-world PNS data of over 6,100 patients, with over 71% demonstrating significant pain relief and/or improvement in quality of life following 60-day percutaneous PNS treatment with the SPRINT PNS System.12,†,‡

Explore The Evidence
wireman expanded without labels
Head / Neck
Shoulder
Back
Hand
Knee
Foot & Ankle

Head-to-toe Treatment Options™

SPRINT PNS may be a solution for a wide variety of moderate-to-severe pain conditions, including:

Chronic back pain
Chronic headache and neck pain
Non-operable joint pain
Postoperative pain
Post-amputation pain
Neuropathic pain
Pain due to nerve trauma

The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves.

First-Line PNS™ treatment

The SPRINT PNS System is a patient-preferred**, low risk alternative to more invasive treatments such as ablation, permanent implants, or surgery. Our breakthrough First-Line PNS treatment is shown to provide significant and sustained pain relief in clinical studies when prior treatments such as opioids or injections have failed. 

SPR Care Continuum

Patient-preferred** treatment

As the least invasive implantable PNS available, the SPRINT PNS System delivers the approach to pain relief patients prefer.

hands holding microlead hands holding microlead

Smallest diameter PNS lead available

radiofrequency ablation graphic radiofrequency ablation graphic

60-day PNS (e.g. SPRINT PNS System) preferred by patients to radiofrequency ablation

SPRINT PNS product SPRINT PNS product

Only FDA-cleared implantable PNS system that does not require incisions or a permanent implant

†The total rate of medical events collected from the product complaint database was approximately 6%, with skin irritation due to adhesive components as the most reported event. 

‡Significant pain relief and/or improvement in quality of life defined as ≥ 50% pain relief and/or at least Minimally Improved on PGIC. 

**In a market research study, SPRINT PNS was a patient-preferred treatment.13

 

References

  1. Wilson RD, et al. PM R 2012. 4: 624-628. 
  2. Rauck RL, et al. Neuromodulation. 2014;17(2):188-197. 
  3. Wilson RD, et al. Am J Phys Med Rehabil. 2014;93(1):1728. 
  4. Wilson RD, et al. Neuromodulation. 2014;17(8):771-776. 
  5. Wilson RD, et al. Am J Phys Med Rehabil. 2017. 96: 191-198. 
  6. Gilmore C, et al. Pain Pract. 2020;20(3):310-320. 
  7. Gilmore C, et al. Reg Anesth Pain Med. 2020;45(1):44-51. 
  8. Gilmore C, et al. Interv Pain Med. 2023;2:100243. 
  9. Goree JH, et al. Neuromodulation. 2024;27:847-861. 
  10. McCormick ZL, et al. Pain Med. 2025;27(4):462-473. 
  11. Gutierrez GG, et al. Headache.  2025;65(10):1776-1787. 
  12. Huntoon M, et al. Pain Phys. 2023;26:273-281.
  13. Staats P, et al. Pain Mgmt. 2021;12(3):371-382.